Results 271 to 280 of about 154,948 (311)
Some of the next articles are maybe not open access.
SGLT2 inhibitors in people with and without T2DM
Nature Reviews Endocrinology, 2020Heart failure and chronic kidney disease are frequent causes of morbidity and mortality in people with type 2 diabetes mellitus. Cardiovascular outcome trials have confirmed benefits of sodium–glucose co-transporter 2 inhibitors on cardiovascular events, cardiovascular deaths, hospitalization for heart failure and renal outcomes.
openaire +2 more sources
T2DM remission — consensus on definition
Nature Reviews Endocrinology, 2021openaire +2 more sources
Adropin as an indicator of T2DM and its complications
Food Science and Human Wellness, 2022Ning Chen
exaly